Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Gene Amplification”

53 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 53 results

Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Early research (Phase 1)Ended earlyNCT02468661
What this trial is testing

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 23
Testing effectiveness (Phase 2)Study completedNCT01520870
What this trial is testing

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Who this might be right for
GlioblastomaBrain Tumor, Recurrent
Grupo Español de Investigación en Neurooncología 49
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Study completedNCT01864681
What this trial is testing

Combination of Metformin With Gefitinib to Treat NSCLC

Who this might be right for
NSCLCEGFR Gene AmplificationAdvanced Cancer+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 224
Testing effectiveness (Phase 2)Ended earlyNCT00748709
What this trial is testing

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Who this might be right for
Neoplasms
Boehringer Ingelheim 20
Large-scale testing (Phase 3)Study completedNCT00320385
What this trial is testing

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 296
Early research (Phase 1)Looking for participantsNCT04429542
What this trial is testing

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal CanalColorectal Cancer+8 more
Bicara Therapeutics 292
Testing effectiveness (Phase 2)UnknownNCT04785729
What this trial is testing

Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Who this might be right for
Safety
Sun Yat-sen University 36
Testing effectiveness (Phase 2)UnknownNCT04136600
What this trial is testing

EGFR Monoclonal Antibody for Advanced Gastric Cancer

Who this might be right for
Gastric CancerCetuximabNimotuzumab
Shanghai Changzheng Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Early research (Phase 1)Active Not RecruitingNCT02609776
What this trial is testing

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Janssen Research & Development, LLC 751
Large-scale testing (Phase 3)UnknownNCT06110663
What this trial is testing

HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 314
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Early research (Phase 1)Looking for participantsNCT07089641
What this trial is testing

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Who this might be right for
IDH Wildtype GlioblastomaRecurrent AstrocytomaIDH Wildtype Recurrent Glioblastoma+2 more
Jonsson Comprehensive Cancer Center 10
Testing effectiveness (Phase 2)UnknownNCT04880811
What this trial is testing

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Who this might be right for
Esophageal Squamous Cell Carcinoma
Peking University 43
Testing effectiveness (Phase 2)Ended earlyNCT04515394
What this trial is testing

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Who this might be right for
Colorectal Neoplasms
EMD Serono Research & Development Institute, Inc. 3
Load More Results